Literature DB >> 24083473

Stroke prevention in atrial fibrillation in older adults: existing knowledge gaps and areas for innovation: a summary of an American Federation for Aging research seminar.

Steven A Lubitz1, Kenneth A Bauer, Emelia J Benjamin, Richard W Besdine, Daniel E Forman, Mahmut E Gurol, Vivek Y Reddy, Daniel E Singer.   

Abstract

Atrial fibrillation (AF) is a common and morbid cardiac arrhythmia that increases in prevalence with advancing age. The risk of ischemic stroke, a primary and disabling hazard of AF, also increases with advancing age. The aging of the population is anticipated to contribute to a rising burden of AF-related morbidity and economic costs, given the close association between the arrhythmia and aging. Recent biological, diagnostic, and therapeutic developments raise hope that AF-related stroke can be largely prevented, yet despite advances in stroke prevention for individuals with AF, numerous scientific and clinical knowledge gaps remain, particularly as these developments are applied to older adults. Given the public health importance of AF-related stroke in elderly adults, a group of clinician-investigators convened on April 5, 2012, to identify promising areas for investigation that may ultimately reduce stroke-related morbidity. This article summarizes the meeting discussion and emphasizes innovative topic areas that may ultimately facilitate the application of novel preventive, diagnostic, and therapeutic insights into the management of older adults with AF. The opinions of those that participated in the meeting limit this report, which may not represent all of the questions that other experts in this field might raise.
© 2013, Copyright the Authors Journal compilation © 2013, The American Geriatrics Society.

Entities:  

Keywords:  atrial fibrillation; elderly; prevention; stroke

Mesh:

Substances:

Year:  2013        PMID: 24083473      PMCID: PMC3801265          DOI: 10.1111/jgs.12456

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  33 in total

Review 1.  Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part I: aging arteries: a "set up" for vascular disease.

Authors:  Edward G Lakatta; Daniel Levy
Journal:  Circulation       Date:  2003-01-07       Impact factor: 29.690

Review 2.  Why do patients with atrial fibrillation not receive warfarin?

Authors:  T J Bungard; W A Ghali; K K Teo; F A McAlister; R T Tsuyuki
Journal:  Arch Intern Med       Date:  2000-01-10

Review 3.  Independent predictors of stroke in patients with atrial fibrillation: a systematic review.

Authors: 
Journal:  Neurology       Date:  2007-08-07       Impact factor: 9.910

4.  Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project).

Authors:  M Lamassa; A Di Carlo; G Pracucci; A M Basile; G Trefoloni; P Vanni; S Spolveri; M C Baruffi; G Landini; A Ghetti; C D Wolfe; D Inzitari
Journal:  Stroke       Date:  2001-02       Impact factor: 7.914

5.  Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis.

Authors:  Carl van Walraven; Robert G Hart; Daniel E Singer; Andreas Laupacis; Stuart Connolly; Palle Petersen; Peter J Koudstaal; Yuchiao Chang; Beppie Hellemons
Journal:  JAMA       Date:  2002-11-20       Impact factor: 56.272

6.  Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study.

Authors:  A S Go; E M Hylek; K A Phillips; Y Chang; L E Henault; J V Selby; D E Singer
Journal:  JAMA       Date:  2001-05-09       Impact factor: 56.272

7.  Lifetime risk for development of atrial fibrillation: the Framingham Heart Study.

Authors:  Donald M Lloyd-Jones; Thomas J Wang; Eric P Leip; Martin G Larson; Daniel Levy; Ramachandran S Vasan; Ralph B D'Agostino; Joseph M Massaro; Alexa Beiser; Philip A Wolf; Emelia J Benjamin
Journal:  Circulation       Date:  2004-08-16       Impact factor: 29.690

8.  Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.

Authors:  P A Wolf; R D Abbott; W B Kannel
Journal:  Stroke       Date:  1991-08       Impact factor: 7.914

Review 9.  Management of intracerebral hemorrhage.

Authors:  Mahmut Edip Gurol; Steven M Greenberg
Journal:  Curr Atheroscler Rep       Date:  2008-08       Impact factor: 5.113

10.  Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials.

Authors: 
Journal:  Arch Intern Med       Date:  1994-07-11
View more
  6 in total

Review 1.  Cerebral microbleeds and macrobleeds: should they influence our recommendations for antithrombotic therapies?

Authors:  Kellen E Haley; Steven M Greenberg; M Edip Gurol
Journal:  Curr Cardiol Rep       Date:  2013-12       Impact factor: 2.931

2.  Ectopy and expectations: can we predict atrial fibrillation, and should we try?

Authors:  Daniel B Kramer; Peter J Zimetbaum
Journal:  Ann Intern Med       Date:  2013-12-03       Impact factor: 25.391

3.  The dichotomy of memantine treatment for ischemic stroke: dose-dependent protective and detrimental effects.

Authors:  Melissa Trotman; Philipp Vermehren; Claire L Gibson; Robert Fern
Journal:  J Cereb Blood Flow Metab       Date:  2014-11-19       Impact factor: 6.200

Review 4.  Efficacy and safety of oral anticoagulants versus aspirin for patients with atrial fibrillation: a meta-analysis.

Authors:  Jing-Tao Zhang; Ke-Ping Chen; Shu Zhang
Journal:  Medicine (Baltimore)       Date:  2015-01       Impact factor: 1.889

5.  Liberal transfusion strategy to prevent mortality and anaemia-associated, ischaemic events in elderly non-cardiac surgical patients - the study design of the LIBERAL-Trial.

Authors:  Patrick Meybohm; Simone Lindau; Sascha Treskatsch; Roland Francis; Claudia Spies; Markus Velten; Maria Wittmann; Erdem Gueresir; Christian Stoppe; Ana Kowark; Mark Coburn; Sixten Selleng; Marcel Baschin; Gregor Jenichen; Melanie Meersch; Thomas Ermert; Alexander Zarbock; Peter Kranke; Markus Kredel; Antonia Helf; Rita Laufenberg-Feldmann; Marion Ferner; Eva Wittenmeier; Karl-Heinz Gürtler; Peter Kienbaum; Marcel Gama de Abreu; Michael Sander; Michael Bauer; Timo Seyfried; Matthias Gruenewald; Suma Choorapoikayil; Markus M Mueller; Erhard Seifried; Oana Brosteanu; Holger Bogatsch; Dirk Hasenclever; Kai Zacharowski
Journal:  Trials       Date:  2019-02-04       Impact factor: 2.279

6.  Florbetapir-PET to diagnose cerebral amyloid angiopathy: A prospective study.

Authors:  M Edip Gurol; J Alex Becker; Panagiotis Fotiadis; Grace Riley; Kristin Schwab; Keith A Johnson; Steven M Greenberg
Journal:  Neurology       Date:  2016-09-07       Impact factor: 9.910

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.